How to Position Pasireotide LAR Treatment in Acromegaly.

Conclusions: In contrast to the current consensus criteria, we recommend a more reluctant use of pasireotide LAR therapy for the treatment of acromegaly. PMID: 30608534 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30608534?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - January 3, 2019 Category: Endocrinology Authors: Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM Tags: J Clin Endocrinol Metab Source Type: research